Moomoo AI 已提取核心訊息
Panbela Therapeutics, Inc. has submitted a response to the U.S. Securities and Exchange Commission (SEC) regarding comments on its Registration Statement on Form S-1, initially filed on January 4, 2024. The correspondence, dated January 22, 2024, addresses the SEC's feedback from a letter dated January 9, 2024, and includes an Amendment No. 1 to the Registration Statement. The SEC had requested revisions to the cover page of the prospectus to specify the volume of Class E, Class F, and Pre-Funded Warrants being registered, as well as to disclose the termination date of the offering. Panbela Therapeutics has made the necessary revisions, including the quantities of the warrants and the specific offering termination date. The company has engaged Roth Capital Partners as its placement agent for the offering, which is being conducted on a best efforts basis. The response to the SEC was reviewed and approved by Panbela Therapeutics and includes input from the company's CEO, Jennifer K. Simpson, CFO Susan Horvath, and legal counsel from Faegre Drinker Biddle & Reath LLP.
Panbela Therapeutics, Inc. has submitted a response to the U.S. Securities and Exchange Commission (SEC) regarding comments on its Registration Statement on Form S-1, initially filed on January 4, 2024. The correspondence, dated January 22, 2024, addresses the SEC's feedback from a letter dated January 9, 2024, and includes an Amendment No. 1 to the Registration Statement. The SEC had requested revisions to the cover page of the prospectus to specify the volume of Class E, Class F, and Pre-Funded Warrants being registered, as well as to disclose the termination date of the offering. Panbela Therapeutics has made the necessary revisions, including the quantities of the warrants and the specific offering termination date. The company has engaged Roth Capital Partners as its placement agent for the offering, which is being conducted on a best efforts basis. The response to the SEC was reviewed and approved by Panbela Therapeutics and includes input from the company's CEO, Jennifer K. Simpson, CFO Susan Horvath, and legal counsel from Faegre Drinker Biddle & Reath LLP.
Panbela Therapeutics, Inc.已就其最初於2024年1月4日提交的S-1表格註冊聲明的評論向美國證券交易委員會（SEC）提交了回應。這封日期爲2024年1月22日的信函回應了美國證券交易委員會對2024年1月9日信函的反饋，其中包括註冊聲明的第1號修正案。美國證券交易委員會已要求修改招股說明書的封面，以具體說明註冊的E類、F類和預融資認股權證的數量，並披露發行的終止日期。Panbela Therapeutics已進行了必要的修改，包括認股權證的數量和具體的發行終止日期。該公司已聘請Roth Capital Partners作爲此次發行的配售代理，該發行正在盡最大努力進行。對美國證券交易委員會的回應已獲得Panbela Therapeutics的審查和批准，其中包括該公司首席執行官詹妮弗·辛普森、首席財務官蘇珊·霍瓦斯以及Faegre Drinker Biddle & Reath LLP法律顧問的意見。
Panbela Therapeutics, Inc.已就其最初於2024年1月4日提交的S-1表格註冊聲明的評論向美國證券交易委員會（SEC）提交了回應。這封日期爲2024年1月22日的信函回應了美國證券交易委員會對2024年1月9日信函的反饋，其中包括註冊聲明的第1號修正案。美國證券交易委員會已要求修改招股說明書的封面，以具體說明註冊的E類、F類和預融資認股權證的數量，並披露發行的終止日期。Panbela Therapeutics已進行了必要的修改，包括認股權證的數量和具體的發行終止日期。該公司已聘請Roth Capital Partners作爲此次發行的配售代理，該發行正在盡最大努力進行。對美國證券交易委員會的回應已獲得Panbela Therapeutics的審查和批准，其中包括該公司首席執行官詹妮弗·辛普森、首席財務官蘇珊·霍瓦斯以及Faegre Drinker Biddle & Reath LLP法律顧問的意見。
有用
沒用
該公告為獨立文件：